Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

NEXT STORY
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, “Off-the-Shelf”, Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
PREV STORY
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma

author_avatar
NASDAQ Market News

Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for Subcutaneous Formulation of Daratumumab

author_avatar
NASDAQ Market News

Dr Roch Doliveux appointed Non-Executive Chairman

author_avatar
NASDAQ Market News